
Clinical study with birch pollen hypoallergen DM-101 continues
First-in-Human clinical study with birch pollen hypoallergen DM-101 has been restarted after a temporary halt.
Read more »Below you can find the latest news releases from Desentum.
First-in-Human clinical study with birch pollen hypoallergen DM-101 has been restarted after a temporary halt.
Read more »Clinical study initiated in January 2020 with birch pollen hypoallergen DM-101 was suspended in March. The main reason for suspension is that the corona virus epidemic has brought about restrictions in the operations at the study site.
Read more »The latest open access paper about our hypoallergen development is available at Nature Scientific Reports.
Read more »Desentum is about to initiate a first-in-human clinical trial with its birch pollen hypoallergen designed to improve immunotherapeutic treatment of birch pollen allergy. In a funding round arranged by Springvest Oy, the company raised 4 million euros that it intends to use for funding clinical...
Read more »Desentumin joukkorahoituskierros käynnistyi 17.9.2019
Read more »